2025-12-30 - Analysis Report
Okay, here's a breakdown of the provided information on Merck & Co. Inc. (MRK), along with analysis:

**1. Return Comparison & Analysis**

*   **Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that develops and manufactures a wide range of healthcare products.
*   **MRK Cumulative Return:** 27.02%
*   **VOO (S&P 500) Cumulative Return:** 103.21%
*   **Divergence:** -80.6 (Relative Divergence: 18.5)

**Analysis:**

*   MRK has significantly underperformed the S&P 500 over the observed period.
*   The relative divergence of 18.5 suggests that the current underperformance is near the lower end of its historical range compared to VOO.  This doesn't mean it *will* improve, but it indicates it's already experiencing considerable relative underperformance compared to the benchmark.

**Alpha, Beta & Financial Performance Analysis**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B)   |
|------------|--------|-------|---------|--------|----------|
| 2015-2017  | 1.0%   | 68.5% | -28.0%  | 0.0    | 133.9    |
| 2016-2018  | 36.0%  | 69.8% | 21.0%   | -0.0   | 181.8    |
| 2017-2019  | 40.0%  | 69.8% | 18.0%   | 0.3    | 216.4    |
| 2018-2020  | 16.0%  | 79.6% | -8.0%   | 0.3    | 194.7    |
| 2019-2021  | 2.0%   | 79.6% | -44.0%  | 0.7    | 191.1    |
| 2020-2022  | 15.0%  | 79.6% | 16.0%   | 0.7    | 276.7    |
| 2021-2023  | 33.0%  | 79.6% | 31.0%   | 0.3    | 271.9    |
| 2022-2024  | -4.0%  | 79.6% | -25.0%  | 0.2    | 248.1    |
| 2023-2025  | -22.0% | 71.5% | -90.0%  | 1.8    | 266.3    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate fluctuates significantly. Performance was strong in the 2016-2019 period, but has significantly declined in recent years (2022-2025).
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant potential for losses.
*   **Alpha:** Alpha (excess return relative to a benchmark) is highly variable. It's negative in several periods, suggesting underperformance relative to the benchmark. The -90% Alpha in 2023-2025 is especially concerning.
*   **Beta:** Beta fluctuates but shows an increase in more recent years, suggesting the stock is becoming more sensitive to market movements. The Beta of 1.8 in 2023-2025 means it is much more sensitive to S&P 500.
*   **Cap (B):** Market Cap has generally increased over time, but there have been fluctuations.

**2. Recent Stock Price Fluctuations**

*   **Close:** 106.78
*   **Last Market:** Price = 106.62, Previous Close = 106.78, Change = -0.15
*   **5-day SMA:** 104.82
*   **20-day SMA:** 101.29
*   **60-day SMA:** 93.31

**Analysis:**

*   The stock price is currently above all its moving averages, which is typically seen as a bullish sign in technical analysis.
*   The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA. This further supports a short-term upward trend.

**3. RSI, PPO, and Divergence Analysis**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI:** 71.04 (Overbought)
*   **PPO:** 0.31
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (2 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** 1.3 (+): 단기상승 (Short-term rise)
*   **Expected Return (%):** -47.6 (Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.)

**Analysis:**

*   **MRI:** The high MRI suggests that the market considers the stock to be relatively safe, despite the previous analysis.
*   **RSI:** The RSI being above 70 indicates that the stock is currently overbought and may be due for a pullback.
*   **PPO:**  The PPO (Percentage Price Oscillator) at 0.31 suggests the short-term moving average is slightly above the long-term moving average, confirming recent upward momentum.
*   **Hybrid Signal:** The "Buy" signal is based on the MRI of 0.9, suggesting a high probability of positive returns, but needs to be considered with the analysis below.
*   **Relative Divergence Change:**  The positive change in divergence over the last 20 days reinforces the recent short-term upward trend.
*   **Expected Return:** The negative expected return of -47.6% is a significant red flag, implying that the model predicts underperformance in the long term compared to the S&P 500.

**4. Recent News & Significant Events (Yahoo Finance)**

*   **Merck (MRK) stock holds steady as Wall Street cools into year-end trade:** This suggests a lack of strong movement or conviction in either direction recently.
*   **Merck & Co., Inc. $MRK Shares Sold by Ethic Inc.:** Institutional selling pressure is generally a negative signal.
*   **Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?:**  This highlights the recent price increase but questions its sustainability given the company's broader challenges.
*   **Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.85:** A dividend increase is generally a positive sign, suggesting management confidence in future cash flows.
*   **MRK Stock Surges 8.3% In A 6-day Winning Spree On BMO Upgrade To $130:**  This explains the recent upward movement and attributes it to an analyst upgrade.  A target price of $130 is significantly above the current price.
*   **Is Merck Stock’s Run Legitimate?:** This article questions whether the stock price increase is justified.

**Analysis:** The news paints a mixed picture.  There's recent positive price movement fueled by an analyst upgrade, but concerns remain about the company's underlying performance and whether the rally is sustainable.  Institutional selling adds to the cautionary signs.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.90)
*   **Opinions:** 26
*   **Target Price (avg/high/low):** 110.04 / 139.00 / 83.00

**Analysis:** The consensus is still "Buy," but it's important to note the wide range in target prices, indicating uncertainty among analysts. The average target price is slightly above the current price, suggesting potential upside.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-05 | 2.32  | 17.28 B$   |
| 2025-08-05 | 1.76  | 15.81 B$   |
| 2025-05-02 | 2.01  | 15.53 B$   |
| 2024-11-06 | 1.25  | 16.66 B$   |
| 2025-11-05 | 1.25  | 16.66 B$   |

**Analysis:**

*   EPS (Earnings Per Share) has been inconsistent, with the most recent quarter being the strongest.
*   Revenue has also fluctuated, with the highest revenue also in the most recent quarter.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|----------------|
| 2025-09-30 | $17.28B  | 77.69%        |
| 2025-06-30 | $15.81B  | 77.50%        |
| 2025-03-31 | $15.53B  | 77.98%        |
| 2024-12-31 | $15.62B  | 75.50%        |
| 2024-09-30 | $16.66B  | 75.51%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-09-30 | $51.85B  | 11.16%   |
| 2025-06-30 | $48.99B  | 9.04%    |
| 2025-03-31 | $48.34B  | 10.51%   |
| 2024-12-31 | $46.31B  | 8.08%    |
| 2024-09-30 | $44.50B  | 7.09%    |

**Analysis:**

*   **Revenue and Profit Margin:** Revenue has generally trended upward, and profit margins are very high and relatively stable.
*   **Equity and ROE:** Equity has been increasing, and ROE (Return on Equity) has also generally increased, indicating improved profitability relative to shareholder equity.

**7. Comprehensive Analysis (Summary)**

*   **Underperformance:** MRK has significantly underperformed the S&P 500 over the analyzed period. The Alpha analysis clearly shows underperformance, especially in recent years.
*   **Technical Indicators:** Recent price action suggests a short-term bullish trend, but the RSI indicates the stock is overbought.
*   **Conflicting Signals:** The MRI suggests the stock is relatively safe, while the *negative* expected return signals potentially significant underperformance compared to the market in the long term. This is a major point of concern.
*   **News and Analyst Sentiment:** News is mixed, with recent positive price movement attributed to an analyst upgrade, but articles questioning the sustainability of the rally and evidence of institutional selling. Analyst consensus remains a "Buy," but target prices vary widely.
*   **Financial Performance:** Recent revenue, EPS, and ROE have improved, which is a positive sign. However, the overall picture remains uncertain.
*   **Risks:** The high MDD indicates significant downside risk. The fluctuating CAGR also highlights the volatile nature of the investment.

**Conclusion:**

Investing in MRK at this point presents a mixed bag of signals. While there's recent positive momentum and improved financials, the stock has significantly underperformed the market and carries significant risks. The negative expected return is a serious warning sign. The high RSI suggests a potential pullback is coming.

**Recommendation:**

Given the conflicting signals and the high level of risk, a cautious approach is warranted. It would be prudent to wait for a pullback and further confirmation of the company's ability to sustain its recent improvements before considering a long-term investment.  Further research into the reasons behind the negative expected return would be crucial. It might also be worthwhile to investigate the specifics of the BMO upgrade and assess its rationale.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.